Minireview: Obesity and breast cancer: A Tale of inflammation and dysregulated metabolism

Molecular Endocrinology

Volumn 27, Issue 5, 2013, Pages 715-725

  Simpson, Evan R ^a   Brown, Kristy A ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

BREAST CANCER; BREAST CARCINOGENESIS; CYTOLOGY; ESTROGEN SYNTHESIS; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

ADIPOSITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOGENESIS; FEMALE; HUMANS; INFLAMMATION; OBESITY;

EID: 84876879033     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1011     Document Type: Review

References (77)

1. Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001;12: 13-21.
2. Vona-Davis L, Rose DP. Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. Curr. Diabetes Rev. 2012;8: 116-130.
3. Hall IJ, Newman B, Millikan RC, Moorman PG. Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol. 2000;151:754-764.
4. Lee E, McKean-Cowdin R, Ma H, et al. Characteristics of triplenegative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011;29:4373-4380.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-444.
6. Koppenol WH, Bounds PL. Contribution to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325-337.
7. Simpson ER, Misso M, Hewitt KN, et al. Estrogen-the good, the bad and the unexpected. Endocr Rev. 2005;26:322-330.
8. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol. 1978;130:448-455.
9. Bulun SE, Simpson ER. Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab. 1994;78:428-432.
10. Olefsky JM, Glass CK. Macrophages, inflammation and insulin resistance. Ann Rev Physiol. 2010;72:219-246.
11. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes. 2009;33:54-66.
12. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12:408-415.
13. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15:635-645.
14. Yde CW, Emdal KB, Guerra B, Lykkesfeldt AE. NFκβ signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res Treat. 2012;135:67-78.
15. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a metaanalysis. Br J Cancer. 2001;84:1188-1192.
16. Ristimäki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632-635.
17. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest. 2012;92:1115-1128.
18. Simpson E, Clyne C, Rubin G, et al. Aromatase-A brief review. Ann Rev Physiol. 2002;64:93-127.
19. 2 liver receptor homologue-1, and aromatase in breast cancer. Cancer Res. 2005;65:657-663.
20. Morris PG, Hudis CA, Giri D, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer Cancer Prev Res. 2011;4:1021-1029.
21. 2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2012;2:356-365.
22. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER. A link between breast cancer and local estrogen synthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab. 1993;77:1622-1628.
23. O'Neill JS, Elton RA, Miller WR. Aromatase activity in adipose tissue from breast quadrants:a link with tumour site. Br Med J (Clin Res Ed). 1988;296:741-743.
24. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab. 1996;81:3843-3849.
25. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
26. Semenza GL. Hypoxia inducible factor 1 and cancer pathogenesis. IUBMB Life. 2008;60:591-597.
27. Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR Complex 1 Mol Cell. 2010;39:171-183.
28. Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8:224-236.
29. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009;9:691-700.
30. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011; 13:1016-1023.
31. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297-308.
32. Katada S, Imhof A, Sassone-Corsi P. Connecting threads: epigenetics and metabolism Cell. 2012;148:24-28.
33. The Encode Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57-74.
34. Paz-Filho G, Lin EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Frontiers Biosci. 2011;16: 1634-1650.
35. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue:the new endocrine organ? A review article. Digest Dis Sci. 2009;54: 1847-1856.
36. Cohen DH, LeRoith D. Obesity, type 2 diabetes and cancer: the insulin and IGF connection. Endocr Relat Cancer. 2012;19:F27-F45.
37. Yecies JL, Manning BD. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 2011;71:2815-2820.
38. Dagon Y, Hur E, Zheng B, Wellenstein K, Cantley LC, Kahn BB. p70S6 kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake. Cell Metab. 2012;16:104-112.
39. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor control of metabolism and cell growth. Future Oncol. 2010;6:457-470.
40. Mak BC, Yeung RS. The tuberous sclerosis complex genes in tumor development. Cancer Invest. 2004;22:588-603.
41. Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint Mol Cell. 2005;18: 283-293.
42. Lacher MD, Pincheira R, Zhu Z, et al. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Oncogene. 2010;29:6543-6556.
43. Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene. 2009;28:2621-2633.
44. Otvos L, Haspinger E, La Russa F, et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 2011;11:90.
45. Brown KA, McInnes KJ, Hunger NI, Oakhill JS, Steinberg GR, Simpson ER. Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription factor 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Res. 2009;69:5392-5399.
46. Brown KA, Simpson ER. Obesity and breast cancer: progress to understanding the relationship. Cancer Res. 2010;70:4-7.
47. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005;437: 1109-1111.
48. Van Nes JGH, de Kruijf EM, Faratian D, et al. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat. 2011;125:671-685.
49. Zhang X, Smith-Warner SA, Collins LC, et al. Use of aspirin, other non-steroidal anti-inflammatory drugs, and acetaminophen and post-menopausal breast cancer incidence. 2012; 30:3468-3477.
50. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclo-oxygenase-2 (COX-2) inhibitors. BMC Cancer. 2006;6:27.
51. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 2004;31(2 Suppl 7):22-29.
52. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest. 2012;92:1115-1128.
53. Prosperi JR, Robertson FM. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions PII, I.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat. 2006;81:55-70.
54. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282:11613-11617.
55. Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM. Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2. Breast Cancer Res Treat. 2012;132:1001-1008.
56. Brown KA, Samarajeewa NU, Simpson ER. Endocrine related cancers and the role of AMPK Mol Cell Endocrinol. 2013;366:170-179.
57. Gallagher EJ, Le Roith D. Diabetes, cancer and Metformin: connections of metabolism and cell proliferation Ann NY Acad Sci. 2011;1243:54-68.
58. El Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethyl biguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275:223-228.
59. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89:1025-1078.
60. Hardie DG, Ross FA, Howley SA. AMP-activated protein kinase: a target for drugs both ancient and modern. Chem Biol. 2012;19: 2222-1236.
61. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of Metformin in operable breast cancer: a pre-operative windowof-opportunity, randomized trial. Breast Cancer Res Treat. 2011; 128:783-794.
62. Oliveras-Ferraros C, Vazquez-Martin A, Menendez JA. Genomewide inhibitory impact of the AMPK activator Metformin on Mphase cell cycle genes in human breast cancer cells. Cell Cycle. 2009;8:1633-1636.
63. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with antidiabetic drug Metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67:6745-6752.
64. Zhuang Y, Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 2008; 3:18.
65. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug Metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576-3586.
66. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic Metformin/ AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 2009;113:101-111.
67. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67: 10804-10812.
68. Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46:2369-2380.
69. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat. 2010;123:591-596.
70. Samarajeewa NU, Ham S, Yang F, Simpson ER, Brown KA. Promoter-specific effects of Metformin on aromatase transcript expression. Steroids. 2011;76:768-771.
71. Lee KH, Hsu EC, Guh JH, et al. Targeting energy metabolic and oncogenic signalling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem. 2011;286:39247-39258.
72. Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin resistant conditions by repressint PTP1B. Cell Metab. 2007;6:307-319.
73. Crandall JP, Oram V, Trandafirescu G, et al. Pilot study of resveratrol in older adults with impaired glucose tolerance J Gerontol A Biol Sci Med Sci. 2012;67:1307-1312.
74. Yoshino J, Conte C, Fontana L, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012;16:658-664.
75. Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates agingrelated metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421-433.
76. Lin JN, Lin VC, Rau KM, et al. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem. 2010;58:1584-1592.
77. Wang Y, Lee KW, Chan FL, Chen S, Leung LK. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol Sci. 2006;92:71-77.